| Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein. | None |
| Hepatocyte growth factor receptor and the c-met oncogene. | None |
| The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. | None |
| Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. | None |
| Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. | None |
| Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. | None |
| The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. | None |
| Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. | None |
| progression of tumors where FH is lost might be boosted by activation of the MET oncogene, which is able to drive cell-autonomous tumor progression | None |
| Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. | None |
| Candidate gene studies in the GWAS era: the MET proto-oncogene, neurocognition, and schizophrenia. | None |
| Oncogenic engagement of the Met receptor is sufficient to evoke angiogenic, tumorigenic, and metastatic activities in rat intestinal epithelial cells. | None |
| Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. | None |
| Targeting the MET oncogene in cancer and metastases. | None |
| Our findings establish that oncogene addiction to MET involves Ron transactivation | None |
| Findings suggest a critical role for Ror1 in malignant phenotypes sustained by the Met oncogene. | None |
| Data suggest that c-Met plays an oncogenic role in the development of NPC and as a potential novel therapeutic target for NPC. | None |
| the met proto-oncogene (MET) and its targets to be associated with this lymphangiogenic phenotype. | None |
| The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth. | None |
| Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. | None |